1022150-57-7 | Sgx-523

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$21.00	$15.00
2mg	95%	in stock	$27.00	$19.00
5mg	95%	in stock	$38.00	$27.00
10mg	95%	in stock	$52.00	$36.00
25mg	95%	in stock	$105.00	$74.00
50mg	95%	in stock	$138.00	$97.00
100mg	95%	in stock	$218.00	$153.00
250mg	95%	in stock	$401.00	$281.00
1g	95%	in stock	$1,210.00	$847.00

Description

• Catalog Number: AE11333
• Chemical Name: Sgx-523
• CAS Number: 1022150-57-7
• Molecular Formula: C18H13N7S
• Molecular Weight: 359.4077
• MDL Number: MFCD16660190
• SMILES: Cn1ncc(c1)c1ccc2n(n1)c(nn2)Sc1ccc2c(c1)cccn2

Computed Properties

• Complexity: 494
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 3
• XLogP3: 2.4

Upstream Synthesis Route

SGX-523 is a potent and selective ATP-competitive inhibitor of the MET receptor tyrosine kinase. In chemical synthesis, SGX-523 can be utilized as a critical reagent for the development and optimization of novel pharmaceutical compounds targeting various types of cancers and other diseases characterized by dysregulated MET signaling pathways. By specifically blocking the activity of MET, SGX-523 can help researchers study the intricate molecular mechanisms involved in cell growth, survival, and metastasis. This targeted approach allows for the precise modulation of MET-related signaling cascades, offering a valuable tool in the design and synthesis of innovative therapeutic agents with potential applications in precision medicine and drug discovery.

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Comprehensive analysis of kinase inhibitor selectivity.

  Nature biotechnology 20111030

• Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

  Chemistry & biology 20101124

• MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.

  Cancer research 20100901

• Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications.

  Drug metabolism and disposition: the biological fate of chemicals 20100801

• An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

  Anti-cancer agents in medicinal chemistry 20100101

• SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.

  Molecular cancer therapeutics 20091201